Arrowhead Pharmaceuticals(GB:0HI3)
$47.17-0.44 (-0.93%)
GB:0HI3
Arrowhead Pharmaceuticals financials statements
$47.17
At close:-0.44 (-0.93%)
Arrowhead Pharmaceuticals (0HI3) Ratios
0 Followers
Arrowhead Pharmaceuticals Ratios
GB:0HI3's free cash flow for Q4 2026 was $-195.83M. For the 2026 fiscal year, GB:0HI3's free cash flow was decreased by $-3.43M and operating cash flow was $-192.40M. See a summary of the company’s cash flow.
| Ratios | Sep 26 | Sep 25 | Sep 24 | Sep 23 | Sep 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.14 | 4.86 | 6.74 | 3.98 | 2.92 |
| Quick Ratio | 4.11 | 4.86 | 6.74 | 3.98 | 3.07 |
| Cash Ratio | 0.20 | 1.16 | 1.00 | 1.05 | 0.78 |
| Solvency Ratio | -0.41 | 0.03 | -0.61 | -0.40 | -0.61 |
| Operating Cash Flow Ratio | -0.87 | 0.92 | -4.49 | -1.46 | -0.98 |
| Short-Term Operating Cash Flow Coverage | -6.80 | 4.49 | -72.98 | -14.57 | -49.04 |
| Net Current Asset Value | $ -398.54M | $ 68.76M | $ -253.27M | $ -58.87M | $ 131.70M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.58 | 0.26 | 0.75 | 0.50 | 0.12 |
| Debt-to-Equity Ratio | 19.88 | 0.79 | 4.59 | 1.41 | 0.20 |
| Debt-to-Capital Ratio | 0.95 | 0.44 | 0.82 | 0.59 | 0.17 |
| Long-Term Debt-to-Capital Ratio | 0.94 | 0.32 | 0.80 | 0.50 | 0.00 |
| Financial Leverage Ratio | 34.55 | 2.97 | 6.15 | 2.82 | 1.74 |
| Debt Service Coverage Ratio | -4.46 | 1.11 | -14.44 | -6.18 | -59.82 |
| Interest Coverage Ratio | -7.55 | 1.10 | -18.58 | -11.19 | 0.00 |
| Debt to Market Cap | 0.09 | 0.06 | 0.32 | 0.10 | 0.00 |
| Interest Debt Per Share | 7.72 | 3.41 | 7.38 | 3.74 | 0.77 |
| Net Debt to EBITDA | -1.55 | 0.85 | -1.33 | -1.55 | 0.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.73% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -139.79% | 16.99% | -16336.47% | -78.16% | -71.01% |
| EBITDA Margin | -133.89% | 19.87% | -15812.81% | -72.97% | -66.72% |
| Operating Profit Margin | -156.86% | 11.86% | -16927.06% | -85.16% | -73.39% |
| Pretax Profit Margin | -160.58% | 6.21% | -17247.54% | -85.78% | -71.01% |
| Net Profit Margin | -160.64% | -0.20% | -16882.37% | -85.27% | -72.39% |
| Continuous Operations Profit Margin | -159.07% | 3.63% | -17169.61% | -86.93% | -72.56% |
| Net Income Per EBT | 100.04% | -3.16% | 97.88% | 99.41% | 101.94% |
| EBT Per EBIT | 102.37% | 52.40% | 101.89% | 100.73% | 96.75% |
| Return on Assets (ROA) | -41.66% | -0.12% | -52.60% | -26.81% | -25.44% |
| Return on Equity (ROE) | -1439.40% | -0.35% | -323.27% | -75.65% | -44.18% |
| Return on Capital Employed (ROCE) | -49.56% | 8.27% | -57.98% | -31.06% | -32.27% |
| Return on Invested Capital (ROIC) | -47.58% | 4.65% | -57.37% | -30.57% | -32.11% |
| Return on Tangible Assets | -41.79% | -0.12% | -52.99% | -27.18% | -25.89% |
| Earnings Yield | -7.81% | -0.04% | -25.84% | -7.12% | -5.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 45.39 | 121.55 | 0.00 | 0.00 | 172.50 |
| Payables Turnover | 0.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 3.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.05 | 1.95 | 0.01 | 0.72 | 1.44 |
| Asset Turnover | 0.26 | 0.60 | 0.00 | 0.31 | 0.35 |
| Working Capital Turnover Ratio | 0.52 | 1.23 | 0.01 | 0.83 | 0.96 |
| Cash Conversion Cycle | -264.27 | 3.00 | 0.00 | 0.00 | 2.12 |
| Days of Sales Outstanding | 8.04 | 3.00 | 0.00 | 0.00 | 2.12 |
| Days of Inventory Outstanding | 117.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 389.58 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 125.31 | 3.00 | 0.00 | 0.00 | 2.12 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.92 | 1.34 | -3.86 | -1.43 | -1.29 |
| Free Cash Flow Per Share | -2.00 | 1.17 | -5.05 | -3.08 | -1.79 |
| Dividend Paid and CapEx Coverage Ratio | -22.67 | 7.92 | -3.27 | -0.87 | -2.58 |
| Capital Expenditure Coverage Ratio | -22.67 | 7.92 | -3.27 | -0.87 | -2.58 |
| Operating Cash Flow Coverage Ratio | -0.27 | 0.49 | -0.54 | -0.40 | -1.67 |
| Operating Cash Flow to Sales Ratio | -0.60 | 0.22 | -130.34 | -0.64 | -0.56 |
| Free Cash Flow Yield | -3.06% | 3.40% | -26.05% | -11.47% | -5.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.81 | -2827.05 | -3.87 | -14.05 | -19.79 |
| Price-to-Sales (P/S) Ratio | 20.56 | 5.56 | 653.40 | 11.98 | 14.33 |
| Price-to-Book (P/B) Ratio | 184.24 | 9.90 | 12.51 | 10.63 | 8.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -32.65 | 29.41 | -3.84 | -8.72 | -18.44 |
| Price-to-Operating Cash Flow Ratio | -34.09 | 25.69 | -5.01 | -18.74 | -25.60 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 28.34 | -0.02 | -0.98 | -0.87 |
| Enterprise Value Multiple | -16.91 | 28.84 | -5.47 | -17.97 | -21.31 |
| Enterprise Value | 10.21B | 4.75B | 3.07B | 3.16B | 3.46B |
| EV to EBITDA | -16.91 | 28.84 | -5.47 | -17.97 | -21.31 |
| EV to Sales | 22.64 | 5.73 | 864.39 | 13.11 | 14.22 |
| EV to Free Cash Flow | -35.95 | 30.30 | -5.08 | -9.55 | -18.30 |
| EV to Operating Cash Flow | -37.53 | 26.47 | -6.63 | -20.51 | -25.40 |
| Tangible Book Value Per Share | 0.32 | 3.71 | 1.52 | 2.58 | 3.85 |
| Shareholders’ Equity Per Share | 0.36 | 3.48 | 1.55 | 2.53 | 3.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.42 | 0.00 | -0.01 | -0.02 |
| Revenue Per Share | 3.18 | 6.20 | 0.03 | 2.24 | 2.31 |
| Net Income Per Share | -5.11 | -0.01 | -5.00 | -1.91 | -1.67 |
| Tax Burden | 1.00 | -0.03 | 0.98 | 0.99 | 1.02 |
| Interest Burden | 1.15 | 0.37 | 1.06 | 1.10 | 1.00 |
| Research & Development to Revenue | 1.64 | 0.73 | 142.46 | 1.47 | 1.22 |
| SG&A to Revenue | 0.45 | 0.15 | 27.27 | 0.38 | 0.51 |
| Stock-Based Compensation to Revenue | 0.15 | 0.08 | 20.83 | 0.32 | 0.50 |
| Income Quality | 0.38 | 5.96 | 0.76 | 0.74 | 0.77 |
Currency in USD
